In ER-negative disease , there was evidence for greater benefit from anthracyclines in the National Epirubicin Adjuvant Trial in patients with CD8 + tumours [ hazard ratio ( HR ) = 0.54 ; 95 % CI 0.37-0 .79 ] versus CD8-negative tumours ( HR = 0.87 ; 95 % CI 0.55-1 .38 ) .